The latest biologic to receive thumbs down from the US Food and Drug Administration is Sanofi’s Dupixent, targeting chronic obstructive pulmonary disease, or COPD. So, that makes it the first biologic to get a nod in the United States.
Paul Hudson, Chief Executive Officer of Sanofi, said: “Dupixent has already shown its potential to change the treatment paradigm of many diseases fueled in part by type 2 inflammation, addressing high unmet medical needs. Over one million patients have been treated worldwide across all approved indications, and today’s approval helps Dupixent become the first and only approved add-on biologic medicine for inadequately controlled COPD.”
Approvals for Dupixent to treat a debilitating condition known as COPD, characterized by persistent respiratory symptoms and limited airflow, will greatly improve the treatment landscape for a debilitating form of disease associated with frequent exacerbations and hospitalizations, among other things, and a poor quality of life.
Chief Executive Officer of The COPD Foundation Jean Wright hailed the approval. Patients with poorly controlled COPD have for a long time waited for new medicines to alleviate their daily suffering from breathlessness, cough, wheeze, exhaustion, and unpredictable hospitalizations. Patients often avoid routine activities that most of us take as a matter of course, as simple as stepping outside to walk or run errands. We are pleased to see this promising new therapeutic option gain approval, which may enable patients to achieve greater control of their disease.
Dupixent’s approval is very important in the process of dealing with the complications of COPD management that seem to veer away from hope. Instead, patients have been faced with limited options for effective treatment. Optimism, however, is very high as healthcare providers and patients explore this new therapeutic avenue regarding health outcomes within the COPD community.
Read More: Click Here